cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Elida Zairina
Contact Email
elida-z@ff.unair.ac.id
Phone
-
Journal Mail Official
jfiki@ff.unair.ac.id
Editorial Address
-
Location
Kota surabaya,
Jawa timur
INDONESIA
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Published by Universitas Airlangga
ISSN : 24069388     EISSN : 25808303     DOI : -
Core Subject : Health, Science, Education,
Chemistry Education Health Professions Medicine & Pharmacology Other
Jurnal ini adalah jurnal peer-review nasional, yang diterbitkan dua kali dalam membahas tentang topik-topik hasil penelitian di bidang pelayanan dan praktik kefarmasian, konsultasi masyarakat, teknologi kefarmasian serta disiplin ilmu kesehatan yang terkait dengan erat. Jurnal ini memfokuskan pada area-area berikut: 1. Farmasi Klinis 2. Farmasi Komunitas 3. Farmasetika 4. Kimia Farmasi 5. Farmakognosi 6. Fitokimia
Arjuna Subject : -
Articles 299 Documents
 26   27   28   29   30 
Effect of Atorvastatin on Lipoprotein Lipase and Lipid Profile in Children with Refractory Nephrotic Syndrome and Hyperlipidemia Nurul Damayanti; Yulistiani; Ninik Asmaningsih Soemyarso; Mariyatul Qibtiyah
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 13 No. 1 (2026): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v13i12026.84-91

Abstract

Background: Statin are Food and Drug Administration (FDA)-approved for hyperlipidemia but remain controversial in children. This study provides novel evidence of the molecular effects of atorvastatin on lipoprotein lipase (LPL) in children with refractory nephrotic syndrome, a population in which such data are limited. Objectives: This study aims to evaluate the effects of atorvastatin on serum lipoprotein lipase (LPL) levels and lipid profile parameters in children with refractory nephrotic syndrome. Methods: Randomized controlled trial (RCT) double-blind study of 31 children with hyperlipidemia and refractory nephrotic syndrome, included pre- and post-test groups. A placebo was given to the first group (n = 18 patients), while atorvastatin was administered to the treatment group (n = 13 patients). Results: Total cholesterol and Low-Density Lipoprotein (LDL) levels decreased significantly after treatment in both groups (p<0.05). In the atorvastatin group, LDL reduction was more pronounced compared to baseline. High-Density Lipoprotein (HDL) and Triglyceride (TG) levels showed no significant changes in either group (p>0.05). Lipoprotein Lipase (LPL) levels increased in the atorvastatin group and decreased in the control group; however, these changes were not statistically significant. No significant differences were observed between the atorvastatin and control groups in terms of changes in lipid profile parameters and LPL levels (p>0.05). Conclusions: Atorvastatin reduced cholesterol and LDL levels within the treatment group, although no significant differences were observed compared to the control group.
In Silico Study of Beluntas Leaves (Pluchea indica) on DPP-4, α-Glucosidase, SGLT-2, and PPAR-γ as Antidiabetic Targets Andri Prasetiyo; Triviana Simanjuntak; Edelburga Suryati Kendok; Matilde Tiwery Dalo; Esti Mumpuni; Esti Mulatsari
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 13 No. 1 (2026): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v13i12026.122-140

Abstract

Background: Diabetes mellitus (DM) is a chronic metabolic disease with a steadily increasing prevalence globally. Long-term use of synthetic antidiabetic drugs is often associated with side effects, making exploration of alternative therapies from natural ingredients important. Pluchea indica L. leaves have been reported as a traditional Indonesian plant empirically used to lower blood sugar levels. Objective: This study aims to explore the potential of active compounds from Pluchea indica L. leaves as candidate multi-target antidiabetic agents through an in silico approach. Methods: An in silico study was conducted using molecular docking with Molegro Virtual Docker (MVD) to evaluate the interaction of four active compounds from beluntas leaves [(+)-Lirioresinol B, β Stigmasterol, (+)-Pinoresinol, and Plucheoside A against diabetes target proteins DPP-4 (PDB: 4FFW), α-glucosidase (PDB: 3L4W), SGLT-2 (PDB: 7VSI), and PPAR-γ (PDB: 5UGM)]. Method validation was performed by re-docking the original ligands (RMSD < 2.0 Å). Lipinski's 5 Rule analysis and ADMET prediction were performed to evaluate the drug-likeness and pharmacokinetic profiles of the compounds. Results: Method validation showed RMSD of 0.31-1.71 Å for all target proteins. Docking results showed that (+)-Pinoresinol had the best affinity as a DPP-4 inhibitor (Rerank score -103.452), (+)-Lirioresinol B as an α-glucosidase inhibitor (-100.173), Plucheoside A as an SGLT-2 inhibitor (-126.555), and β Stigmasterol as a PPAR-γ agonist (-131.023). Lipinski's 5 Rules analysis showed that all compounds most often violated 1 criterion (PSA). ADMET predictions showed an acceptable pharmacokinetic profile with low toxicity. Conclusion: The active compounds from beluntas leaves show potential as multi-target antidiabetic agents with good binding affinity to diabetes target proteins. These findings are still predictive and require further validation through in vitro and in vivo studies to confirm their biological activity, selectivity, safety, and pharmacological relevance as effective antidiabetic candidates in the future.
The Impact of Clinical Pharmacists on Improving Outcomes for Cancer Patients – A Systematic Review Agnes Evonella Pangaribuan; Nadia Farhanah Syafhan; Yovita Diane Titiesari
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 13 No. 1 (2026): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v13i12026.92-111

Abstract

Background: Clinical pharmacists play a crucial role in the management and care of patients with cancer. Objective: This systematic review evaluated the effectiveness of clinical pharmacist-led interventions on clinical outcomes in patients with cancer undergoing chemotherapy. Methods: A comprehensive literature review was performed using PubMed, Scopus, and ScienceDirect, focusing on randomized controlled trials (RCTs) published between January 2010 and May 2025. The search included relevant keywords and MeSH terms such as “Antineoplastic Agents,” “Pharmaceutical Services,” and “Clinical pharmacists.” This study focused on English-language journals reporting on studies of patients with cancer undergoing chemotherapy, evaluating clinical pharmacist-led interventions. The initial search yielded 3,803 articles screened. After a thorough evaluation of the titles, abstracts, and full texts, along with an assessment of quality and risk of bias, 10 trials were included in the analysis.  Results: Clinical pharmacists help patients take their medications more effectively, improving patient adherence by up to 30%. They also reduce problems with side effects, adverse effects, and medication incompatibilities, with one study showing a 77.3% success rate in reducing problems with medications. Patient satisfaction was high at 93%, and quality of life improved. One study found cost savings of USD 269,420 over eight months of use. The intervention included messaging and vaccination programs for older adults, conducted in-person and online. Conclusion: Clinical pharmacist-led interventions are crucial for improving medication adherence, ensuring patient safety, and enhancing clinical outcomes in patients undergoing chemotherapy. Incorporating clinical pharmacists as integral members of the oncology care team is a valuable strategy.
Bioactivity Screening of Endophytic Fungi Isolated from Nypa fruticans Leaves: Antioxidant, Antibacterial, and Cytotoxic Evaluations Khiky Dwinatrana; Gefi Dwi Hermanto; Intan Lestari; Ananda Ogesta; Helmice Afriyeni; Rustini
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 13 No. 1 (2026): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v13i12026.150-159

Abstract

Background: Nypa fruticans is a mangrove palm known to harbor diverse endophytic microorganisms with potential bioactivity. However, studies on the biological properties of endophytic fungi are scarce. Objective: This study aimed to evaluate the antioxidant, antibacterial, and cytotoxic activities of endophytic fungi isolated from N. fruticans leaves and to characterize their secondary metabolite profiles. Methods: Eight fungal isolates (NF1–NF8) were obtained and screened for antioxidant activity using the DPPH radical-scavenging method, antibacterial activity against Staphylococcus aureus and Escherichia coli using the disc diffusion method, and cytotoxicity using the Artemia salina lethality test. The most active isolates were further analyzed using thin-layer chromatography (TLC) and phytochemical tests. Results: The isolates exhibited varying bioactivities, with NF5 showing antioxidant potential (IC₅₀ = 152.6 µg/mL) and NF7 showing the strongest antibacterial (19.1 ± 0.25 mm inhibition zone) and cytotoxic activities (LC₅₀ = 198.81 µg/mL). TLC and reagent detection confirmed the presence of phenolic compounds in NF5 and terpenoid compounds in NF7, corresponding to their biological profiles. Conclusion: The endophytic fungi from N. fruticans leaves exhibited significant antioxidant, antibacterial, and cytotoxic activities, indicating their potential as novel sources of natural bioactive metabolites, particularly in palm-associated fungal communities.
Cost of Illness of Diabetic Foot Ulcer in Lower Middle-Income Countries: A Systematic Review Sinta Wulandari; Alfadea Irbah Allizaputri; Libriansyah; Yunita Nita
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 13 No. 1 (2026): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v13i12026.72-83

Abstract

Background: Diabetic foot ulcers (DFU) are a consequence of diabetes mellitus (DM) that cause a significant financial burden on the healthcare system, society, and individuals. The average prevalence of DFU was 6.3%. The cost of diabetic foot care is 50% to 200% higher than that of primary diabetes care. Objective: This systematic review aimed to provide an overview of the variations in the economic burden of DFU in lower middle-income countries (LMICs). Methods: This systematic review examined studies published in English that investigated the costs associated with evaluating diabetic foot disease in LMICs. COCHRANE, CINAHL, DOAJ, EMBASE, GOOGLE SCHOLAR, Ovid MEDLINE, PUBMED, SCIENCE DIRECT, and SCOPUS were used as literature sources without publication date restrictions. Results: A systematic search identified six eligible studies conducted across multiple countries. The studies were published between 2000 and 2024, with study durations ranging from 6 to 12 months. These studies showed large variations in cost components, estimating both direct and indirect costs of the disease. The total costs incurred for DFU vary among LMICs, ranging from USD 379.39 to USD 60,014.81 per year. Conclusion: DFU impose a significant economic burden in LMICs, with substantial variations in cost estimates owing to differences in methodology and data availability. Future studies on the cost burden of DFU should be conducted on a larger scale to obtain more accurate cost estimates.
Formulation and Optimization Spanlastic Gel Loaded Epigallocatechin Gallate for Transdermal Delivery Mhd. Yogi Munthe; Nuzul Wahyuning Diyah; Esti Hendradi
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 13 No. 1 (2026): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v13i12026.60-71

Abstract

Background: Epigallocatechin gallate (EGCG) is an antioxidant that has been shown to have various pharmacological activities in both in vivo and in vitro studies. However, EGCG has low oral bioavailability. Alternative routes of administration, such as transdermal, can be used to overcome the stratum corneum of the skin, which provides a barrier that inhibits drugs from entering the dermal microcirculation to prove systemic availability. This limitation can be overcome by applying an elastic nanosized delivery system such as Spanlastic. Objective: To develop a spanlastic gel as an EGCG delivery system for transdermal application. Methods: Sp-EGCG was prepared by injecting ethanol with Tween 60 as the EA and Span 60 as the VB. Design Expert Software was then used to determine the optimum formula to be added to the gel base and tested for ex vivo permeation and in vitro release. Results: Optimization of 13 Sp-EGCG formulas resulted in entrapment efficiencies (79.2925–86.1921) %, zeta potentials (23.86-38.06) -mV, and vesicle sizes (129.933–225.233) nm. The optimal formulation consisted of Span 60 and Tween 80 in a 6:4 ratio and a rotation speed of 1000rpm. The pH value of the Sp-EGCG gel was 5.057 ± 0.016, with a viscosity of 795.43 ± 4.224 cPs and a spreadability of 5.833 ± 0.024 cm. In vitro release results showed that Sp-EGCG provided controlled release following the Higuchi model, while ex vivo permeability test results showed that Sp-EGCG gel increased the amount of EGCG penetration by up to 2.51 times. Conclusion: EGCG was successfully formulated into Sp-EGCG, and F3 was identified as the optimum formula, with a VS of 129.33 nm, ZP of-38.06 mV, and EE of 86.19%. The Sp-EGCG gel increased EGCG permeability in the skin.
Formulation and Evaluation of n-Hexane Tamarindus indica Extract Spray Gel for In Vivo Anti-inflammatory Activities Rachmad Tri Wahyudi; Solideo Gloria Simanjuntak; Daffa Rizky; Faishal Nashif Guntoro; Ajeng Budi Purwati; Bachtiar Rifai Pratita Ihsan; Queen Intan Nurrahmah
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 13 No. 2 (2026): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Tamarind (Tamarindus indica) contains various constituents, the biggest of which is the flavonoid group. Flavonoids themself have many health benefits, one of them is anti-inflammatory activity. Currently, it is necessary to develop herbal ingredients as an alternative to synthetic topical anti-inflammatory therapy. Optimizing flavonoid extraction, formulation development, and activity evaluation were carried out to increase tamarind's anti-inflammatory activity. Objective: This research aims to formulate and evaluate spray gel formulation containing tamarind pulp extract and its effectiveness as an anti-inflammatory treatment. Methods: The extraction method used is to optimize the solvent ratio and duration (days) parameter, then process it using a statgraph to produce an optimal method. The best extraction method chosen was determined by aluminum chloride methods. The spray gel formulation was optimized with HPMC concentration parameters. Activity evaluations were performed to evaluate the reduction in edema volume. Results: Based on extraction optimization, a method was chosen with a solvent ratio of 1:4 for 3 days produced 5.608 mgQE flavonoid. Formulation with 1% HPMC was the best result from three different HPMC concentration variations. From in vivo testing, it concluded that Spray Gel Tamarind Extract (TE) containing 1.8% and 3% extract was the most optimum to decrease edema or inflammation compared with positive control (p-value < 0.05). Conclusion: Spray gel containing Tamarindus indica extract presents a promising pathway for developing effective topical anti-inflammatory pharmaceutical formulations.
The Effect of Drugs Related Problems on Therapy Outcomes in Hospitalized Chronic Kidney Disease Patients Irma Susanti; Rizki Ananda Siswanto; Devi Ristian Octavia; Imanda Dyah Rahmadhani
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 13 No. 2 (2026): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Chronic Kidney Disease (CKD) is characterized by a progressive decline in kidney function, which can cause various complications and increase the potential for drug-related problems (DRPs). DRPs are events that link actual or potential drug therapy to patient health outcomes. Objective: This study aimed to determine the effect of DRPs on the outcomes of CKD patient therapy. Methods: This study used a retrospective approach with sampling conducted at Muhammadiyah Hospital Lamongan from January 2024 to December 2024. The study population consisted of 250 patients, and the research sample was selected using purposive sampling, which met the inclusion criteria, resulting in a total sample of 155 patients. The inclusion criteria were inpatients suffering from CKD with or without complications, CKD patients with stage ≥ 2, and an age range of ≥ 25 years. Results: The findings of this study indicate that DRPs in CKD patients were due to drug interactions (78,07%), drug duplication (10,32%), and polypharmacy (24,51%). The outcome of therapy in CKD patients was based on achieved GFR values (76,78%) and those not achieved (23,22%). The results of the study showed that there was influenced the outcome of therapy, with  a p-value of 0,040. Conclusion: The influence of DRPs on therapeutic outcomes in patients has is significant, with their presence reducing the effectiveness of therapy and increasing the risk of complications. Therefore, early identification and management of DRPs are necessary to achieve optimal therapeutic results.
Hematologic Safety Profile on a Recombinant SARS-CoV-2 Protein Subunit Vaccine Formulated with Alum and CpG 1018 (IndoVac®) Endang Mahati; Nani Maharani; Yetty Movieta Nency; Nur Farhanah; Rebriarina Hapsari; Dimas Tri Anantyo; Mulyono; Glenn Fernandez Yeremia; Muhammad Fajar Shodiq; Setyo Gundi Pramudo; Ulfa Luthfiani Nurkamila Mutiara
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 13 No. 2 (2026): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v13i22026.173-183

Abstract

Background: mRNA vaccines have been associated with idiopathic thrombocytopenic purpura (ITP). The development of inactivated vaccines and the addition of adjuvants, such as aluminum salts (alum) and cytosine-phosphate-guanine (CpG), are expected to enhance their safety and effectiveness. Objective: We examined the changes in hematological profiles in response to various doses of a recombinant SARS-CoV-2 protein subunit vaccine formulated with Alum and CpG oligodeoxynucleotide 1018 (CpG 1018). Methods: This research involved an analysis of data from a Phase I, observer-blind, randomized, controlled trial in healthy participants aged–18-70 years old in Indonesia. The subjects were divided into five groups: Sinovac® (A), 12.5 µg of SARS-CoV-2 RBD subunit recombinant protein and 750 µg (group B) or 1500 µg (group C) Alum+CpG1018, 25 µg of SARS-CoV-2 RBD subunit recombinant protein and 750 µg (group D) or 1500 µg (group E) Alum+CpG1018. Hematological parameter fluctuations were compared from baseline (V0), 7 days after the initial dose (V1a), and 14 days after the second dose (V2a). Results: There were no significant differences in red blood cell parameters between the groups after vaccination. Platelet levels were stable in all groups at all time points. The different leukocyte counts showed a slight fluctuation in neutrophils, eosinophils, lymphocytes, and monocytes during the study. All hematological changes were within the normal range. Conclusion: Variation in the dosage of recombinant SARS-CoV-2 protein subunit vaccine formulated with Alum and CpG 1018 showed safety parameters on the hematologic profile.
Pharmacist-Led Tailored Interventions to Adress Medication-Adherence Barriers and Improve Health-Related Quality of Life in Patients with Heart Failure: A Prospective Pre-Post Study Zahrah Tatta Ramadhanty; Deny Wilson Amanda Sitorus; Wenny Putri Nilamsari; Hendri Susilo; Mochamad Yusuf Alsagaff; Khusnul Fitri Hamidah; Ching Siang Tan; Khalid Ahmad Ali Al Sunaidar
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 13 No. 2 (2026): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Nonadherence to heart failure (HF) therapy affects mortality and hospitalization. Pharmacists play a crucial role in addressing barriers to adherence; however, the implementation of tailored, patient-specific interventions has not been explored. Objective: To evaluate changes in medication adherence and health-related quality of life (QOL) following a pharmacist-led, barrier-spesific intervention among outpatients with chronic heart failure.  Methods: This prospective, single-centre, one-group pre-post study was conducted at the Cardiology and Vascular Polyclinic of a secondary hospital in Indonesia. Patients were observed over two months and received educational interventions, medication reminders, and simplified medication instructions. Medication adherence was assessed using the ARMS-7, while QOL was measured using SF-36. The McNemar test was used to assess medication adherence, and the Wilcoxon test was used to evaluate QOL improvement. Results: Forty participants completed the study, with more than half being male (aged < 60 years). The results indicated that forgetting to get prescriptions filled (85%) and forgetting to take medication (17.5%) were the major barriers to adherence to medication. Eighty percent of patients showed improved medication adherence (p < 0.05). Physical, mental, and social functions improved the most (p < 0.05). Conclusion: The findings underscore the effectiveness of a tailored intervention in significantly improving medication adherence and QOL among patients with HF, highlighting its ability to address specific barriers.

Page 29 of 30 | Total Record : 299

 26   27   28   29   30 

Filter by Year

2016 2026


Reset
Filter By Issues
All Issue Vol. 13 No. 2 (2026): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 13 No. 1 (2026): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 12 No. 3 (2025): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 12 No. 2 (2025): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 12 No. 1 (2025): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 11 No. 3 (2024): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 11 No. 2 (2024): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 11 No. 1 (2024): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 3 (2023): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 2 (2023): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 1 (2023): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 9 No. 3 (2022): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 9 No. 2 (2022): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 9 No. 1 (2022): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 8 No. 3 (2021): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 8 No. 2 (2021): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 8 No. 1 (2021): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 7 No. 2 (2020): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 7 No. 1 (2020): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 7 No. 1SI (2020): Special Issue: Seminar Inovasi Teknologi dan Digitalisasi pada Pelayanan Kefa Vol. 6 No. 2 (2019): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 6 No. 1 (2019): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 5 No. 2 (2018): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 5 No. 1 (2018): Jurnal Farmasi dan Ilmu Kefarmasian Indonesia Vol. 4 No. 2 (2017): Jurnal Farmasi dan Ilmu Kefarmasian Indonesia Vol. 4 No. 1 (2017): Jurnal Farmasi dan Ilmu Kefarmasian Indonesia Vol. 3 No. 2 (2016): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 3 No. 1 (2016): Jurnal Farmasi dan Ilmu Kefarmasian Indonesia More Issue